EA039658B1 - Перенацеливающие cd3/cd38 t-клетки гетеродимерные иммуноглобулины и способы их получения - Google Patents

Перенацеливающие cd3/cd38 t-клетки гетеродимерные иммуноглобулины и способы их получения Download PDF

Info

Publication number
EA039658B1
EA039658B1 EA201790961A EA201790961A EA039658B1 EA 039658 B1 EA039658 B1 EA 039658B1 EA 201790961 A EA201790961 A EA 201790961A EA 201790961 A EA201790961 A EA 201790961A EA 039658 B1 EA039658 B1 EA 039658B1
Authority
EA
Eurasian Patent Office
Prior art keywords
seq
antibody
amino acid
human
protein
Prior art date
Application number
EA201790961A
Other languages
English (en)
Russian (ru)
Other versions
EA201790961A1 (ru
Inventor
Ромейн Оллиер
Самюэль Хоу
Рами Лиссилаа
Дарко СКЕГРО
Джонатан Бэк
Original Assignee
Икнос Сайенсиз С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Икнос Сайенсиз С.А. filed Critical Икнос Сайенсиз С.А.
Publication of EA201790961A1 publication Critical patent/EA201790961A1/ru
Publication of EA039658B1 publication Critical patent/EA039658B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201790961A 2015-05-08 2015-11-03 Перенацеливающие cd3/cd38 t-клетки гетеродимерные иммуноглобулины и способы их получения EA039658B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15167034 2015-05-08
PCT/EP2015/075628 WO2016071355A1 (fr) 2014-11-04 2015-11-03 Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production

Publications (2)

Publication Number Publication Date
EA201790961A1 EA201790961A1 (ru) 2017-10-31
EA039658B1 true EA039658B1 (ru) 2022-02-22

Family

ID=53059011

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790961A EA039658B1 (ru) 2015-05-08 2015-11-03 Перенацеливающие cd3/cd38 t-клетки гетеродимерные иммуноглобулины и способы их получения

Country Status (20)

Country Link
EP (1) EP3215541A1 (fr)
JP (3) JP2018501297A (fr)
KR (1) KR20170078831A (fr)
CN (1) CN107207596A (fr)
AU (1) AU2015341884B2 (fr)
BR (1) BR112017009263A2 (fr)
CA (1) CA2965745C (fr)
CL (1) CL2017001090A1 (fr)
CO (1) CO2017005240A2 (fr)
EA (1) EA039658B1 (fr)
HK (1) HK1244014A1 (fr)
IL (1) IL251848A0 (fr)
MA (1) MA40894A (fr)
MX (1) MX2017005814A (fr)
MY (1) MY186929A (fr)
NZ (1) NZ732019A (fr)
PE (1) PE20171041A1 (fr)
PH (1) PH12017500819A1 (fr)
SG (1) SG11201703313SA (fr)
WO (1) WO2016071355A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
EP3620473A1 (fr) 2013-01-14 2020-03-11 Xencor, Inc. Nouvelles protéines hétérodimères
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
AU2014292924B2 (en) 2013-07-25 2019-11-21 Cytomx Therapeutics, Inc Multispecific antibodies, multispecific activatable antibodies and methods of using the same
JP2016538275A (ja) 2013-11-04 2016-12-08 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造
CN111410691B (zh) 2014-03-28 2024-02-13 Xencor公司 结合至cd38和cd3的双特异性抗体
JP7020909B2 (ja) * 2014-07-25 2022-02-16 シトムクス セラピューティクス，インコーポレイティド 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
LT3223845T (lt) 2014-11-26 2021-08-25 Xencor, Inc. Heterodimeriniai antikūnai, kurie suriša cd3 ir cd20
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
WO2016086196A2 (fr) 2014-11-26 2016-06-02 Xencor, Inc. Anticorps hétérodimériques se liant aux antigènes cd3 et cd38
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
US10227410B2 (en) 2015-12-07 2019-03-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
US10787518B2 (en) 2016-06-14 2020-09-29 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
KR20190020341A (ko) 2016-06-28 2019-02-28 젠코어 인코포레이티드 소마토스타틴 수용체 2에 결합하는 이종이량체 항체
AU2018259039A1 (en) * 2017-04-24 2019-11-07 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of EGFR positive cancers
WO2018224441A1 (fr) * 2017-06-05 2018-12-13 Numab Innovation Ag Nouveaux anticorps anti-cd3
IL271128B1 (en) 2017-06-05 2024-06-01 Numab Therapeutics AG New anti-3CD antibodies
US11780930B2 (en) 2017-06-08 2023-10-10 Black Belt Therapeutics Limited CD38 modulating antibody
EP3635003A1 (fr) * 2017-06-08 2020-04-15 Black Belt Therapeutics Limited Anticorps permettant de moduler cd38
JP6833851B2 (ja) * 2017-08-10 2021-02-24 グリフォルズ ダイアグノスティック ソリューションズ インコーポレイティド 組み換えヒトｃｄ３８細胞外ドメインを含む組成物および／または方法および／またはキット
US11542338B2 (en) 2017-08-16 2023-01-03 Black Belt Therapeutics Limited CD38 modulating antibody
WO2019035938A1 (fr) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Molécules multispécifiques se liant à bcma et leurs utilisations
JP7299873B2 (ja) 2017-08-16 2023-06-28 ブラック ベルト セラピューティクス リミテッド Ｃｄ３８抗体
US11472889B2 (en) 2017-10-14 2022-10-18 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
EP3856347A1 (fr) * 2018-09-25 2021-08-04 Ichnos Sciences SA Quantification d'anticorps dans des échantillons biologiques
KR102353568B1 (ko) * 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
WO2020152290A1 (fr) 2019-01-23 2020-07-30 Encefa Compétiteurs de cd31 et utilisations associées
US20220177582A1 (en) * 2019-03-13 2022-06-09 Ichnos Sciences SA Non-consensus glycosylation of bispecific antibodies
WO2020237173A1 (fr) * 2019-05-23 2020-11-26 VelosBio Inc. Molécules de liaison bispécifiques anti-ror1/anti-cd3
US20220227887A1 (en) * 2019-06-11 2022-07-21 Ono Pharmaceutical Co., Ltd. Immunosuppressant
CN110551222B (zh) * 2019-08-27 2023-06-06 重庆市畜牧科学院 一种新型双功能抗体及其用途
EP4039707A4 (fr) * 2019-09-30 2022-11-16 Harbour Biomed (Shanghai) Co., Ltd Anticorps de ciblage de cd3, anticorps bispécifique et son utilisation
CN113493519B (zh) * 2020-03-19 2022-12-27 浙江道尔生物科技有限公司 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白
CA3176391A1 (fr) * 2020-04-24 2021-10-28 Memorial Sloan-Kettering Cancer-Center Anticorps anti-cd3 et utilisations associees
WO2021231976A1 (fr) 2020-05-14 2021-11-18 Xencor, Inc. Anticorps hétérodimères qui se lient à l'antigène membranaire spécifique de la prostate (psma) et cd3
AU2021292231A1 (en) * 2020-06-17 2023-01-19 Y-Mabs Therapeutics, Inc. CD38 antibodies for the treatment of human diseases
KR102607909B1 (ko) 2020-08-19 2023-12-01 젠코어 인코포레이티드 항-cd28 조성물
EP4305065A1 (fr) 2021-03-10 2024-01-17 Xencor, Inc. Anticorps hétérodimères qui se lient au cd3 et au gpc3

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008047242A2 (fr) * 2006-10-19 2008-04-24 Sanofi-Aventis Nouveaux anticorps anti-cd38 pour le traitement du cancer
WO2010151792A1 (fr) * 2009-06-26 2010-12-29 Regeneron Pharmaceuticals, Inc. Anticorps bispécifiques facilement isolés avec un format d'immunoglobuline native
WO2011154453A1 (fr) * 2010-06-09 2011-12-15 Genmab A/S Anticorps dirigés contre le cd38 humain
WO2012092612A1 (fr) * 2010-12-30 2012-07-05 Takeda Pharmaceutical Company Limited Anticorps anti-cd38
WO2012131555A2 (fr) * 2011-03-25 2012-10-04 Glenmark Pharmaceuticals S.A. Immunoglobulines hétéro-dimériques
EP2522724A1 (fr) * 2009-12-25 2012-11-14 Chugai Seiyaku Kabushiki Kaisha Procédé de modification de polypeptide pour purifier un multimère de polypeptide
WO2014049003A1 (fr) * 2012-09-25 2014-04-03 Glenmark Pharmaceuticals S.A. Purification d'immunoglobulines hétérodimères
WO2014068114A1 (fr) * 2012-11-05 2014-05-08 Morphosys Ag Anticorps radiomarqué et ses utilisations
WO2015063339A1 (fr) * 2013-11-04 2015-05-07 Glenmark Pharmaceuticals S.A. Production de cellules t reciblant des immunoglobulines héréro-dimériques

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2541489T3 (es) * 2004-02-06 2015-07-21 Morphosys Ag Anticuerpos humanos anti-CD38 y usos para ellos
CN101218256B (zh) * 2005-03-23 2017-04-19 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
KR101472250B1 (ko) * 2005-10-12 2014-12-11 모르포시스 아게 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008047242A2 (fr) * 2006-10-19 2008-04-24 Sanofi-Aventis Nouveaux anticorps anti-cd38 pour le traitement du cancer
WO2010151792A1 (fr) * 2009-06-26 2010-12-29 Regeneron Pharmaceuticals, Inc. Anticorps bispécifiques facilement isolés avec un format d'immunoglobuline native
EP2522724A1 (fr) * 2009-12-25 2012-11-14 Chugai Seiyaku Kabushiki Kaisha Procédé de modification de polypeptide pour purifier un multimère de polypeptide
WO2011154453A1 (fr) * 2010-06-09 2011-12-15 Genmab A/S Anticorps dirigés contre le cd38 humain
WO2012092612A1 (fr) * 2010-12-30 2012-07-05 Takeda Pharmaceutical Company Limited Anticorps anti-cd38
WO2012131555A2 (fr) * 2011-03-25 2012-10-04 Glenmark Pharmaceuticals S.A. Immunoglobulines hétéro-dimériques
WO2014049003A1 (fr) * 2012-09-25 2014-04-03 Glenmark Pharmaceuticals S.A. Purification d'immunoglobulines hétérodimères
WO2014068114A1 (fr) * 2012-11-05 2014-05-08 Morphosys Ag Anticorps radiomarqué et ses utilisations
WO2015063339A1 (fr) * 2013-11-04 2015-05-07 Glenmark Pharmaceuticals S.A. Production de cellules t reciblant des immunoglobulines héréro-dimériques

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ALMAGRO JUAN C; FRANSSON JOHAN: "Humanization of antibodies", FRONTIERS IN BIOSCIENCE, FRONTIERS IN BIOSCIENCE, ALBERTSON, NY, US, vol. 13, 1 January 2008 (2008-01-01), US , pages 1619 - 1633, XP009126790, ISSN: 1093-9946 *
GRAILLE M, ET AL.: "Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: Structural basis for recognition of B-cell receptors and superantigen activity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 97, no. 10, 9 May 2000 (2000-05-09), pages 5399 - 5404, XP002284947, ISSN: 0027-8424, DOI: 10.1073/pnas.97.10.5399 *
J. DECKERT ET AL: "SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 20, no. 17, 1 September 2014 (2014-09-01), US, pages 4574 - 4583, XP055239997, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-14-0695 *
JONATHAN H ELLIS , KAREN A BARBER , ALISON TUTT , CHRISTINE HALE , ALAN P LEWIS , MARTIN J GLENNIE , GEORGE T STEVENSON , J SCOTT : "Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma.", THE JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO., US, vol. 155, no. 2, 15 July 1995 (1995-07-15), US , pages 925 - 937, XP002146232, ISSN: 0022-1767 *
LUM L G, AL-KADHIMI Z.: "Development and prospects for bispecific antibody-based therapeutics in cancer and other applications", EXPERT OPINION ON DRUG DISCOVERY, INFORMA HEALTHCARE, LONDON, GB, vol. 3, no. 9, 1 September 2008 (2008-09-01), London, GB , pages 1081 - 1097, XP002752851, ISSN: 1746-0441, DOI: 10.1517/17460441.3.9.1081 *
M. DE WEERS, Y.-T. TAI, M. S. VAN DER VEER, J. M. BAKKER, T. VINK, D. C. H. JACOBS, L. A. OOMEN, M. PEIPP, T. VALERIUS, J. W. SLOO: "Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors", THE JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, vol. 186, no. 3, 1 February 2011 (2011-02-01), pages 1840 - 1848, XP055210884, ISSN: 00221767, DOI: 10.4049/jimmunol.1003032 *
POTTER K N; LI Y; PASCUAL V; CAPRA J D: "Staphylococcal protein A binding to VH3 encoded immunoglobulins.", INTERNATIONAL REVIEWS OF IMMUNOLOGY., HARWOOD ACADEMIC PUBLISHERS, LONDON., GB, vol. 14, no. 4, 1 January 1997 (1997-01-01), GB , pages 291 - 308, XP008116757, ISSN: 0883-0185 *
ROBEN P W, SALEM A N, SILVERMAN G J: "VH3 family antibodies bind domain D of staphylococcal protein A.", THE JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO., US, vol. 154, no. 12, 15 June 1995 (1995-06-15), US , pages 6437 - 6445, XP002508063, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
AU2015341884B2 (en) 2020-09-17
CN107207596A (zh) 2017-09-26
EP3215541A1 (fr) 2017-09-13
JP7403505B2 (ja) 2023-12-22
NZ732019A (en) 2022-07-29
MY186929A (en) 2021-08-26
CA2965745C (fr) 2023-12-05
BR112017009263A2 (pt) 2018-01-30
CA2965745A1 (fr) 2016-05-12
AU2015341884A1 (en) 2017-06-08
JP2021184722A (ja) 2021-12-09
CO2017005240A2 (es) 2017-10-31
HK1244014A1 (zh) 2018-07-27
WO2016071355A1 (fr) 2016-05-12
JP2019214582A (ja) 2019-12-19
SG11201703313SA (en) 2017-05-30
PE20171041A1 (es) 2017-07-19
MA40894A (fr) 2017-09-12
MX2017005814A (es) 2017-08-02
IL251848A0 (en) 2017-06-29
CL2017001090A1 (es) 2018-01-05
JP2018501297A (ja) 2018-01-18
EA201790961A1 (ru) 2017-10-31
KR20170078831A (ko) 2017-07-07
PH12017500819A1 (en) 2017-10-02

Similar Documents

Publication Publication Date Title
JP7403505B2 (ja) Ｃｄ３／ｃｄ３８ ｔ細胞再標的化ヘテロ二量体免疫グロブリン及びその製造方法
US11891454B2 (en) Production of T cell retargeting hetero-dimeric immunoglobulins
US12006367B2 (en) CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
EA045935B1 (ru) Антитела к cd3 и их применение
OA17758A (en) Production of T cell retargeting heterodimeric immunoglobulins.